Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies

Tofacitinib is an oral small molecule JAK inhibitor for the treatment of ulcerative colitis. Relationships between plasma tofacitinib concentration and efficacy were characterized using exposure‐response (E‐R) models, with demographic and disease covariates evaluated as potential predictors of effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Arnab, Tsuchiwata, Shinichi, Nicholas, Timothy, Cook, Jack A., Modesto, Irene, Su, Chinyu, D’Haens, Geert R., Sandborn, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322343/
https://www.ncbi.nlm.nih.gov/pubmed/35380740
http://dx.doi.org/10.1002/cpt.2601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322343/
https://www.ncbi.nlm.nih.gov/pubmed/35380740
http://dx.doi.org/10.1002/cpt.2601

Ejemplares similares